What drugs does LONG GROVE PHARMS make?

LONG GROVE PHARMS has 13 FDA-approved drugs including NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE.

What therapeutic areas does LONG GROVE PHARMS focus on?

LONG GROVE PHARMS focuses primarily on Metabolic and Oncology and 1 other therapeutic areas.

Data updated: Mar 10, 2026

LONG GROVE PHARMS

MetabolicOncologyCardiovascular

Pharma

LONG GROVE PHARMS is a pharmaceutical company focused on Metabolic, Oncology, Cardiovascular. Key products include VASOPRESSIN IN SODIUM CHLORIDE 0.9%.

2008

Since

Drugs

Trials

131

Approved (2yr)

Key Drugs

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

norepinephrine bitartrate

alpha-adrenergic receptor 1 indications · 2022

Recent Activity

ESTRADIOL 2026-02-02

METHADONE HYDROCHLORIDE 2026-01-22

Manufacturing (CMC)

ESTRADIOL 2026-01-22

Labeling

SODIUM BICARBONATE 2026-01-13

METHADONE HYDROCHLORIDE 2025-12-23

Labeling

METHADONE HYDROCHLORIDE 2025-12-23

Labeling

METHADONE HYDROCHLORIDE 2025-12-22

Labeling

METHADONE HYDROCHLORIDE 2025-12-22

Labeling

METHADONE HYDROCHLORIDE 2025-12-22

Labeling

METHADONE HYDROCHLORIDE 2025-12-22

Labeling

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 40%

2 drugs

Oncology 40%

2 drugs

Cardiovascular 20%

1 drugs

Pipeline Strength ProEarly access

Competitors ProEarly access

Merck big-pharma

Oncology, Cardiovascular, Metabolic

Johnson & Johnson big-pharma

Oncology, Cardiovascular, Metabolic

Bayer big-pharma

Oncology, Cardiovascular, Metabolic

AstraZeneca big-pharma

Oncology, Cardiovascular, Metabolic

Boehringer Ingelheim big-pharma

Metabolic, Oncology, Cardiovascular

LONG GROVE PHARMS

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (13)

Active (10)

Discontinued (2)

Company Info